Compare INTZ & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | INTS |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 13.7M |
| IPO Year | 2020 | 2021 |
| Metric | INTZ | INTS |
|---|---|---|
| Price | $0.41 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.67 |
| AVG Volume (30 Days) | ★ 173.6K | 12.5K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,015,000.00 | N/A |
| Revenue This Year | $22.62 | N/A |
| Revenue Next Year | $26.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.47 | $0.22 |
| 52 Week High | $1.56 | $8.06 |
| Indicator | INTZ | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 42.22 |
| Support Level | N/A | $0.22 |
| Resistance Level | $0.89 | $3.58 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 3.15 | 36.74 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.